Vycor Medical (VYCO) 10-Q 2009 Q2 Quarterly report

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D. C.  20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal quarter ended_________June 30, 2009_______________

[   ]  TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

For the transition period from    to

VYCOR MEDICAL, INC.

(Exact name of small business issuer as specified in its charter)

Delaware	333-149782	20-3369218
(State of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

80 Orville Drive, Suite 100, Bohemia, New York 11716

(Address of principal executive offices) (Zip code)

Issuer’s telephone number: (631) 244 1435

Securities registered under Section 12(g) of the Exchange Act:

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x   No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes o    No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer o	Accelerated filer o
Non-accelerated filer o   (Do not check if a smaller reporting company)	Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes o   No x

There were 26,356,638 shares outstanding of registrant’s common stock, par value $.001 per share, as of July 27, 2009.

Transitional Small Business Disclosure Format (check one):   Yes o No x

TABLE OF CONTENTS

	PART I
Item 1.	Financial Statements	1
	Consolidated Balance Sheets as of June 30, 2009 (unaudited) and December 31, 2008	1
	Unaudited Consolidated Statements of Operations for the three and six months ended June 30, 2009 and June 30, 2008	2
	Unaudited Consolidated Statements of Cash Flows for the six months ended June 30, 2009 and 2008	4
	Notes to Unaudited Consolidated Financial Statements	5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operation	23
Item 3	Quantitative and Qualitative Disclosures About Market Risk	32
Item 4	Controls and Procedures	32
	PART II
Item 1.	Legal Proceedings	33
Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	33
Item 3	Defaults Upon Senior Securities	33
Item 4.	Submission of Matters to a Vote of Security Holders	33
Item 5.	Other Information	33
Item 6.	Exhibits	34
SIGNATURES

PART 1

ITEM 1. FINANCIAL STATEMENTS

VYCOR MEDICAL, INC.
Balance Sheet
June 30, 2009
		June 30,		December 31,
		2009		2008
		(unaudited)		(audited)
ASSETS
Current Assets
	Cash	$	54,927	$	196,138
	Accounts receivable		27,141		89,765
	Inventory		49,093		71,527
	Prepaid expenses		17,890		7,040
			149,051		364,470
Fixed assets, net			202,483		213,958
Other assets:
	Patents, net of accumulated amortization		37,968		42,507
	Website, net of accumulated amortization		8,597		10,152
	Security deposits		2,350		2,350
			48,915		55,009
TOTAL ASSETS		$	400,449	$	633,437
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current Liabilities
	Accounts payable	$	345,189	$	313,611
	Accrued interest		129,089		88,588
	Accrued liabilities		183,026		75,468
	Notes payable		40,000		-
	Current portion of long-term debt		1,122,500		1,077,197
			1,819,804		1,554,864
Long-term debt less current portion			-		-
TOTAL LIABILITIES			1,819,804		1,554,864
STOCKHOLDERS' DEFICIT
	Preferred stock, $1.00 par value, 10,000,000 shares authorized, none
	issued and outstanding		-		-
	Common Stock, $0.001 par value,
	100,000,000 shares authorized,
	26,356,638 and 25,463,455 shares issued and outstanding		26,357		25,463
	at June 30, 2009 and December 31, 2008, respectively
	Additional  Paid-in Capital		2,961,442		2,788,415
	Accumulated Deficit		(4,407,154)		(3,735,305)
			(1,419,355)		(921,427)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT		$	400,449	$	633,437
See accompanying notes to financial statements

1

VYCOR MEDICAL, INC.
Statement of Operations
	For the three months ended June 30,
	2009		2008
	(unaudited)		(unaudited)
Revenue	$	42,301	$	-
Cost of Goods Sold
Beginning Inventory		56,101		-
Cost of goods purchased		-		-
Goods available for sale		56,101		-
Less: Clinical samples		(1,677)		-
Less: Ending inventory		(49,093)		-
Total Cost of Goods Sold		5,331		-
Gross Profit		36,970		-
Operating expenses:
Research and development		-		9,228
General and administrative		234,045		381,365
Total Operating expenses		234,045		390,593
Operating loss		(197,075)		(390,593)
Interest expense		54,639		157,099
Net Loss	$	(251,714)	$	(547,692)
Loss Per Share
Basic and diluted	$	(0.01)	$	(0.02)
Weighted Average Number of Shares Outstanding		26,356,638		22,109,164
See accompanying notes to financial statements

2

VYCOR MEDICAL, INC.
Statement of Operations
	For the six months ended June 30,
	2009		2008
	(unaudited)		(unaudited)
Revenue	$	112,389	$	-
Cost of Goods Sold
Beginning Inventory		71,527		-
Cost of goods purchased		-		-
Goods available for sale		71,527		-
Less: Clinical samples		(7,600)		-
Less: Ending inventory		(49,093)		-
Total Cost of Goods Sold		14,834		-
Gross Profit		97,555		-
Operating expenses:
Research and development		-		15,561
General and administrative		576,011		859,993
Total Operating expenses		576,011		875,554
Operating loss		(478,456)		(875,554)
Interest expense		193,393		250,598
Net Loss	$	(671,849)	$	(1,126,152)
Loss Per Share
Basic and diluted	$	(0.03)	$	(0.05)
Weighted Average Number of Shares Outstanding		26,207,774		21,426,705
See accompanying notes to financial statements

3

VYCOR MEDICAL, INC.
Statement of Cash Flows
	For the six months ended June 30,
	2009		2008
	(unaudited)		(unaudited)
Cash flows from operating activities:
Net loss	$	(671,849)	$	(1,126,152)
Adjustments to reconcile net loss to cash
used in operating activities:
Amortization of intangible assets		6,245		5,359
Depreciation of fixed assets		11,474		215
Amortization of debt discount expense		145,303		216,175
Share based compensation		62,296		23,584
Shares issued for consulting services		5,000		307,536
Interest satisifed with stock conversion		6,625		-
Changes in assets and liabilities:
Accounts receivable		62,624		2,565
Inventory		22,434		-
Prepaid expenses		(10,850)		(107,478)
Security deposit		-		(2,242)
Accounts payable		31,578		(160,078)
Accrued interest		40,501		35,540
Accrued liabilities		107,558		56,434
Cash used in operating activities		(181,061)		(748,542)
Cash flows used in investing activities:
Purchase of fixed assets		-		(8,614)
Acquisition of website		-		(6,500)
Acquisition of patents		(150)		(21,370)
Cash used in investing activities		(150)		(36,484)
Cash flows from financing activities:
Proceeds from sale of equity		-		240,000
Payment on Notes Payable-GC Advisors		-		(15,457)
Proceeds from Notes Payable		40,000		-
Proceeds from Fountainhead Convertible Note Payable		-		300,000
Proceeds from Regent Convertible Note Payable		-		1,000,000
Payment on Optimum Health Services Loan Payable		-		(100,000)
Cash provided by financing activities		40,000		1,424,543
Net increase (decrease) in cash		(141,211)		639,517
Cash at beginning of period		196,138		15,739
Cash at end of period	$	54,927	$	655,256
Supplemental Disclosures of Cash Flow information:
Interest paid:	$	-	$	-
Taxes paid	$	-	$	-
Non-Cash Tranactions:
Warrants, options and stock issued for debt financing	$	250,000	$	23,950
See accompanying notes to financial statements

4

VYCOR MEDICAL, INC.

NOTES TO FINANCIAL STATEMENTS

JUNE 30, 2009 

1. BASIS OF PRESENTATION

The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of management, all adjustments, consisting of normal recurring accruals considered necessary for a fair presentation, have been included.  Operating results for the six months and three months ended June 30, 2009 are not necessarily indicative of the results that may be expected for the year ending December 31, 2009.  For further information, refer to the financial statements and footnotes thereto for the year ended December 31, 2008.

2. FORMATION AND BUSINESS OF THE COMPANY

Business Description

Vycor Medical, LLC, (the “Company”) was formed in June 17, 2005 under the laws of the State of New York. The Company converted its entity form on August 14, 2007 from a New York Limited Liability Company to a Delaware Corporation with 16,048 of common stock exchange for each partnership unit with 1122 units outstanding at date of conversion. The assets, liabilities and operations of the Company did not change pursuant to this reorganization, and the accompanying financial statements are presented as if the change occurred on the first day of the earliest period presented; thus all are references to number of shares prior to the date of conversion are based upon the common stock equivalent of the units. The Company’s business plan is to develop and market a commercially feasible surgical access system for sale to hospitals and medical professionals.

3. ACCOUNTING POLICIES

Research and Development

The Company expenses all research and development costs as incurred. For the six months ended June 30, 2009 and 2008, the amounts charged to research and development expenses were $0 and $15,561, respectively.

Concentration of Credit Risk

The Company maintains cash balances at various financial institutions. Accounts at each institution are insured by the Federal Deposit Insurance Corporation up to $250,000. The Company's accounts at these institutions may, at times, exceed the federally insured limits. The Company has not experienced any losses in such accounts.

Fair Values of Financial Instruments

At June 30, 2009, fair values of cash, accounts receivable, accounts payable, and accrued expenses short term promissory notes, approximate their carrying amount due to the short period of time to maturity. The fair value of the Company’s long term debt is based on the present value using a discount rate comparable with borrowing rates available to the Company along with various fair value model calculations used to value certain debt related securities.

5

VYCOR MEDICAL, INC.

NOTES TO FINANCIAL STATEMENTS

JUNE 30, 2009

3. ACCOUNTING POLICIES (CON’T)

Property and equipment

The Company records property and equipment at cost and calculates depreciation using the straight-line method over the estimated useful life of the assets, which is estimated to be between three and ten years.

Income taxes

The Company accounts for income taxes in accordance with SFAS 109, Accounting for Income Taxes. This statement prescribes the use of the liability method whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. The Company has provided a full valuation allowance against the gross deferred tax asset as of June 30, 2009 as it is more likely than not that this deferred tax asset may not realized.

Uses of estimates in the preparation of financial statements

The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Critical estimates include depreciation, amortization of intangible assets, and the fair values of options and warrant included in the determination of debt discounts and share based compensation.

Patents

The Company capitalizes legal and related costs associated with the establishment of patents for its products. Costs associated with the development of the patented item or processes are charged to research and development costs as incurred. The costs associated with the establishment of the patents are amortized over the life of the patent.

The Company reviews existing patents as well as those in the approval process for impairment on an annual basis using a present value, cash flow method pursuant to Statement of Financial Accounting Standards 142, Goodwill and Other Intangible Assets. Since the Company’s patents are either very new or still in the process of approval, the Company does not believe that any impairment of these amounts exists.

Revenue Recognition

The Company records revenue, pursuant to Staff Accounting Bulletin Topic 13(a) when a completed contract for the sale exists, title transfers to the buyer and the product is invoiced and shipped to the customer. The Company sells a surgical access system which has already cleared the U.S. FDA 510(k) review process. It has been granted a 510(k) number for marketing the system to hospitals and other medical professionals. The Company does not

6

VYCOR MEDICAL, INC.

NOTES TO FINANCIAL STATEMENTS

JUNE 30, 2009

3. ACCOUNTING POLICIES (CON’T)

expect the need to provide for product returns or warrantee costs but will review such potential costs after the commencement of sales.

Educational and marketing expenses

The Company may incur costs for the education of customers on the uses and benefits of its products. The Company will expense such costs as a component of selling, general and administrative costs as such costs are incurred.

Website Costs

The Company capitalizes the costs associated with the acquisition of hardware and development tools as well as the creation of database tools in connection with the Company’s website pursuant to Statement of Position 98-1 and Emerging Issues Task Force 00-20. Other costs including the development of functionality and identification of software tools are expensed as incurred.

Stock-Based Compensation

Prior to January 1, 2006, the Company accounted for stock-based compensation arrangements in accordance with the provisions of Accounting Principles Board Opinion No. 25 (APB 25), Accounting for Stock Issued to Employees, and related interpretations, and followed the minimum value disclosure provisions of Statement of Financial Accounting Standards NO. 123 (SFAS 123), Accounting for Stock-Based Compensation.  Under APB 25, compensation expense is based on the difference, if any, on the date of the grant, between the fair value of the Company’s stock and the exercise price. Stock-based compensation determined under APB 25 is recognized over the option vesting period.

Prior to the adoption of a stock option plan adopted on February 13, 2008, the Company only issued share based compensation to consultants for goods or services. The Company accounted for these transactions under guidance for Emerging Issues Task Force Abstract No. 96-18, Accounting for Equity Instruments that are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling Goods or Services. Under EITF 96-18, options, warrants, and stock are recorded at their fair value on the measurement date. The Company remeasured the fair value of such instruments granted at each reporting period until performance under the consulting arrangements were completed and the measurement date was reached. The Company records the expense of such services on the estimate fair value of the equity instrument using the Black-Sholes pricing model. The initial expense is recognized over the term of the service agreement.

For future awards to employees, the Company will adopt the fair value provisions of the Statement of Financial Accounting Standards No. 123(R) (SFAS 123R), Share-Based Payment, which supersedes its previous accounting under APB 25. SFAS 123(R) requires the recognition of compensation expense for future stock-based compensation awards to employees. Using a fair-value-based method, for costs related to all share-based payments including stock options.  SFAS 123R requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. All option grants valued after January 1, 2006 will be expensed on a straight-line basis over the vesting period.

7

VYCOR MEDICAL, INC.

NOTES TO FINANCIAL STATEMENTS

JUNE 30, 2009

3. ACCOUNTING POLICIES (CON’T)

Fair Values of Assets and Liabilities

Effective January 1, 2008, the Company adopted Statement of Financial Accounting Standards No. 157, Fair Value Measurements (SFAS 157), which provides a framework for measuring fair value under GAAP. SFAS 157 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. SFAS 157 requires that valuation techniques maximize the use of observable inputs and minimize the use of unobservable inputs. SFAS 157 also establishes a fair value hierarchy, which prioritizes the valuation inputs into three broad levels.

There are three general valuation techniques that may be used to measure fair value, as described below:

a)    Market approach – Uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities. Prices may be indicated by pricing guides, sale transactions, market trades, or other sources;

b)    Cost approach – Based on the amount that currently would be required to replace the service capacity of an asset (replacement cost); and

c)    Income approach – Uses valuation techniques to convert future amounts to a single present amount based on current market expectations about the future amounts (includes present value techniques and option-pricing models). Net present value is an income approach where a stream of expected cash flows is discounted at an appropriate market interest rate.

Financial assets and liabilities are valued using either level 1 inputs based on unadjusted quoted market prices within active markets or using level 2 inputs based primarily on quoted prices for similar assets or liabilities in active or inactive markets.  For certain long-term debt, fair value is based on present value techniques using inputs derived principally or corroborated from market data. Using level 3 inputs using management’s assumptions about the assumptions market participants would utilize in pricing the asset or liability. In the Company’s case this entailed assumptions used in pricing models for attached warrant calculations. Valuation techniques utilized to determine fair value are consistently applied.

 The Company’s long-term debt is the only item that is subject to SFAS 157 as of June 30, 2009 as follows:

Other observable inputs (level 2)	$	950,000
Unobservable inputs (level 3)	$	172,500

8

VYCOR MEDICAL, INC.

NOTES TO FINANCIAL STATEMENTS

JUNE 30, 2009

3. ACCOUNTING POLICIES (CON’T)

Net Loss Per Share

Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is based on the weighted-average common shares outstanding during the period plus dilutive potential common shares calculated using the treasury stock method.  Such potentially dilutive shares are excluded when the effect would be to reduce a net loss per share. The Company’s potential dilutive shares, which include outstanding common stock options, convertible notes payable and warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.

The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented:

	June 30,		December 31,
	2009		2008
Stock options outstanding		1,050,000		1,707,894
Warrants to purchase common stock		5,610,452		6,460,920

Recently Issued Accounting Standards

In December 2007, the Financial Accounting Standards Board (“FASB”) issued SFAS No. 160, Interests in Consolidated Financial Statements - an amendment of ARB No. 51, (“SFAS 160”), that establishes and expands accounting and reporting standards for the non-controlling interest in a subsidiary. SFAS 160 is effective for business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2008. This Statement is required to be adopted by us in the first quarter of the Company's fiscal year 2009. The effect the adoption of SFAS 160 will have on the Company's financial statements will depend on the nature and size of any acquisitions the Company completes in the future.

In December 2007, the FASB issued SFAS No. 141R, Business Combinations, (“SFAS 141R”), which impacts the accounting for business combinations. The statement requires changes in the measurement of assets and liabilities required in favor of a fair value method consistent with the guidance provided in SFAS 157. Additionally, the statement requires a change in accounting for certain acquisition related expenses and business adjustments which no longer are considered part of the purchase price. Adoption of this standard is required for fiscal years beginning after December 15, 2008. Early adoption of this standard is not permitted. The statement requires

9

VYCOR MEDICAL, INC.

NOTES TO FINANCIAL STATEMENTS

JUNE 30, 2009

3. ACCOUNTING POLICIES (CON’T)

prospective application for all acquisitions after the date of adoption. The effect the adoption of SFAS 141R will have on the Company's financial statements will depend on the nature and size of any acquisitions the Company completes in the future.

In March 2008, the FASB issued SFAS No. 161, Disclosures About Derivative Instruments and Hedging Activities, (“SFAS 161”), which requires enhanced disclosures about an entity’s derivative and hedging activities in order to improve the transparency of financial reporting. SFAS 161 is effective for financial statements issued for fiscal years and interim periods beginning after November 15, 2008, with early application encouraged. The Company does not anticipate the adoption of this statement to have a material effect on its consolidated financial position and results of operations.

In May 2008, the FASB issued SFAS No. 162, The Hierarchy of Generally Accepted Accounting Principles, (“SFAS No. 162”), which identifies the sources of accounting principles and the framework for selecting the principles used in the preparation of financial statements. SFAS No. 162 is effective 60 days following the SEC’s approval of the Public Company Accounting Oversight Board (“PCAOB”) amendments to AU Section 411, The Meaning of Present Fairly in Conformity with Generally Accepted Accounting Principles. The Company does not anticipate the adoption of this statement to have a material effect on its consolidated financial position and results of operations.

In May 2008, the FASB issued FASB Staff Position (FSP) No. 14-1, Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement), (“FSP 14-1”) which specifies that issuers of these instruments should separately account for the liability and equity components in a manner that reflects the entity’s nonconvertible debt borrowing rate when interest cost is recognized in subsequent periods. FSP 14-1 is effective for financial statements issued for fiscal years beginning after December 15, 2008, and interim periods within those fiscal years. FSP 14-1 is also to be applied retrospectively to all periods presented except if these instruments were not outstanding during any of the periods that are presented in the annual financial statements for the period of adoption but were outstanding during an earlier period. The Company does not anticipate the adoption of this statement to have a material effect on its consolidated financial position and results of operations.

In June 2008, the FASB ratified EITF Issue 07-5, Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity’s Own Stock, (“EITF 07-5”). Paragraph 11(a) of SFAS No 133, Accounting for Derivatives and Hedging Activities, (“SFAS 133”) specifies that a contract that would otherwise meet the definition of a derivative but is both (a) indexed to the Company’s own stock and (b) classified in stockholders’ equity in the statement of financial position would not be considered a derivative financial instrument. EITF 07-5 provides a new two-step model to be applied in determining whether a financial instrument or an embedded feature is indexed to an issuer’s own stock and thus able to qualify for the SFAS 133 paragraph 11(a) scope exception. EITF 07-5 will be effective for the first annual reporting period beginning after December 15, 2008, and early adoption is prohibited. While the Company is currently still evaluating the effects of adoption of EITF 07-5, it is expected that adoption may result in the reclassification of the Company’s warrants from equity to liabilities recorded at fair value and additionally could result in bifurcation and fair value accounting for the conversion rights embedded in the Company’s Series A preferred stock.

10

VYCOR MEDICAL, INC.

NOTES TO FINANCIAL STATEMENTS

JUNE 30, 2009

3. ACCOUNTING POLICIES (CON’T)

In June 2008, the FASB issued FASB Staff Position Emerging Issues Task Force (EITF) No. 03-6-1, Determining Whether Instruments Granted in Share-Based Payment Transactions Are Participating Securities (“FSP EITF No. 03-6-1”).  Under FSP EITF No. 03-6-1, unvested share-based payment awards that contain rights to receive nonforfeitable dividends (paid or unpaid) are participating securities, and should be included in the two-class method of computing EPS. FSP EITF No. 03-6-1 is effective for fiscal years beginning after December 15, 2008, and interim periods within those years, and is not expected to have a significant impact on the Company’s financial statements.

The Company does not believe that any other recently issued, but not yet effective accounting standards will have a material effect on the Company’s consolidated financial position, results of operations or cash flows.

Going Concern

The Company’s financial statements have been presented on a basis that contemplates the realization of assets and the satisfaction of liabilities in the normal course of business and assumes the Company will continue as a going concern. The Company has incurred losses since its inception, including a net loss of $671,849 for the six months ended June 30, 2009, and the Company expects to continue to incur substantial additional losses in the future, including additional development costs, costs related to marketing and manufacturing expenses. The Company has incurred negative cash flows from operations since inception. As of June 30, 2009, the Company had a stockholders’ deficiency of $1,419,355 and cash and cash equivalents balance of $54,927. The Company also has certain debt obligations that were not paid by their respective due dates. In these circumstances the Company believes it may not have enough cash to meet its various cash needs through August 2009 unless the Company is able to obtain additional cash from the issuance of debt or equity securities.  There is no assurance that additional funds from the issuance of equity will be available for the Company to finance its operations on acceptable terms. If adequate funds are not available, the Company may have to delay development or commercialization of products or technologies that the Company would otherwise seek to commercialize, or cease operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.

4. LONG-TERM DEBT

 As of June 30, 2009 and December 31, 2008, long-term debt consists of:

June 30, 2009 December 31, 2008

11

VYCOR MEDICAL, INC. NOTES TO FINANCIAL STATEMENTS JUNE 30, 2009 4.LONG-TERM DEBT (CON’T)
On December 15, 2006 the Company entered into a Convertible debenture, in the amount of $172,500 payable to Fountainhead Capital Partners Limited (FCPL), with interest at the “Applicable Federal Rate” as defined in sec. 1274 (d) of the Internal Revenue Code, initially due June 21, 2007. The Debenture may be transferred or exchanged only in compliance with the Security Act of 1933, as amended and applicable state securities laws. The Holder is entitled at its option to convert debenture into a number of shares of common stock calculated to be equal to be ten percent of the issued and outstanding aggregate shares of the Company on the date of issuance of the Debenture. The following discloses the calculation the conversion price and the 1,979,456 conversion shares:
Number of membership units outstanding at 12/21/2006	1,110.11	Units
The note was for 10% of Units post-money (1,110.11/90%):	1233.46	Units
FCPL is entitled to 10% of the units equal to	123.346	Units
Each unit converted into 16,048 shares	1,979,456	Shares
The Company has computed a beneficial conversion feature of $111,099 which resulted in a debt discount of such amount which is being amortized over the life of the loan to interest expense. The Company had used $0.19 per share in the computation of the beneficial conversion feature as it represents sales of private placements of the Company’s securities at the time of entering into the debenture. The Holder has the sole option to extend the due date of this debenture and has extended principal and interest payments until February 15, 2009. On April 1, 2009, FCPL agreed to extend the maturity date of the debenture to August 15, 2009. In consideration for the extension, the Company agreed to modify the effective conversion price from $0.08715 to $0.07545 per share, and VYCOR MEDICAL, INC.

12

NOTES TO FINANCIAL STATEMENTS JUNE 30, 2009 4.LONG-TERM DEBT (CON’T) other additional anti-dilution provisions in favor of FCPL. In conjunction with the convertible debenture the Company issued a warrant to Fountainhead Capital Partners Limited to purchase 50.22 Membership Units of the Company (805,931 shares of common stock) at $.50 per share for five years. The warrant’s fair value of $0.13 per share was calculated using the Black-Scholes Valuation Model, using the following assumptions: volatility of 99%, dividend rate of 0%, approximate risk free interest rate of 4.5% and a five year warrant life. The warrant resulted in an additional debt discount of $61,401 which is being amortized over the term of the debt. In conjunction with this debt the Company also entered into an agreement with Fountain Capital Partners Limited (FCPL) which granted to FCPL an option to invest up to $1,850,000 for three years in exchange for issuing new convertible debentures due two years from the issuance of these new notes and included with the exercise of this option would be a warrant to purchase up to 3,017,409 shares at a price of $0.44 per share. The debenture is convertible into up to 5,652,954 shares of common stock.   No value was assigned to the options as there was no acquired beneficial conversion feature or acquisition of the warrants.  The note reflects an unamortized discount of $0 and $3,450 as of June 30, 2009 and December 31, 2008, respectively.	172,500	169,050
On February 15, 2008 the Company entered into a $150,000 Convertible Debenture payable to Fountainhead Capital Partners Limited, with interest at 6% per annum, due but not paid, on or before February 15, 2009. In addition, the debenture accrues interest at the rate of 12% per annum while the Maker is in default of the stated repayment terms. The Holder is entitled to convert all or any amount of the principal face amount of the debenture then outstanding into shares of common stock of the Company at the conversion price of $0.1230 per share, subject to adjustment and does not require bifurcation. The Company has computed a beneficial conversion feature debt discount of $81,707, which is being amortized over the life of the loan. The note reflects an unamortized discount of $0 and $10,213 as of June 30, 2009 and December 31, 2008, respectively.	150,000	139,787
On February 15, 2008 the Company entered into a $500,000 Convertible Debenture, payable to Regent Private Capital, LLC, with VYCOR MEDICAL, INC. NOTES TO FINANCIAL STATEMENTS

13

JUNE 30, 2009 4.LONG-TERM DEBT (CON’T) interest at 6% per annum, due but not paid, on or before February 15, 2009. In addition, the debenture accrues interest at the rate of 12% per annum while the Maker is in default of the stated repayment terms. The Holder is entitled to convert all or any amount of the principal face amount of the debenture then outstanding into shares of common stock of the Company at the Conversion price of $0.1230 per share, subject to adjustment and does not require bifurcation. The Company has computed a beneficial conversion feature debt discount of $272,358, which is being amortized over the life of the loan. Subsequently, Regent assigned the principal amount of each note to Altcar Investments and Derek Johansen.  On December 15, 2008, Johansen converted $250,000 of the debenture into 2,032,520 shares of common stock.  This resulted in the recognition of unamortized beneficial conversion feature debt discount attributable to the debenture of $17,023. Further, on March 23, 2009, Altcar Investments converted $100,000 of the debenture plus accrued interest into 866,867 shares of common stock. The unamortized discount on the $150,000 debt as of June 30, 2009 and $250,000 debt as of December 31, 2008 is $0 and $17,023, respectively.	150,000	232,977
On April 15, 2008 the Company entered into a $150,000 Convertible Debenture payable to Fountainhead Capital Partners Limited, with interest at 6% per annum, due but not paid, on or before April 15, 2009. In addition, the debenture accrues interest at the rate of 12% per annum while the Maker is in default of the stated repayment terms. The Holder is entitled to convert all or any amount of the principal face amount of the debenture then outstanding into shares of common stock of the Company at the conversion price of $0.1230 per share, subject to adjustment and does not require bifurcation. The Company has computed a beneficial conversion feature debt discount of $81,707 which is being amortized over the life of the loan. The unamortized discount as of June 30, 2009 and December 31, 2008 is $0 and $23,831, respectively.	150,000	126,169
On April 22, 2008 the Company entered into a $500,000 Convertible Debenture, payable to Regent Private Capital, LLC, with interest at 6% per annum, due on or before April 22, 2009. In addition, the debenture accrues interest at the rate of 12% per annum while the VYCOR MEDICAL, INC. NOTES TO FINANCIAL STATEMENTS

14

JUNE 30, 2009 4.LONG-TERM DEBT (CON’T) Maker is in default of the stated repayment terms. The Holder is entitled to convert all or any amount of the principal face amount of the debenture then outstanding into shares of common stock of the Company at the Conversion price of $0.1230 per share, subject to adjustment and does not require bifurcation. The Company has computed a beneficial conversion feature debt discount of $272,358, which is being amortized over the life of the loan. The unamortized discount as of June 30, 2009 and December 31, 2008 is $0 and $90,786, respectively.		500,000		409,214
All discounts are being amortized on a straight line basis that approximates effective yield method under EITF 98-5.
Total long-term debt:		1,122,500		1,077,197
Less current portion of debt		1,122,500		1,077,197
Long-term portion of debt	$	-	$	-

 The following is a schedule of future minimum loan payments:

Twelve months ending June 30,	Amount
2010	$	1,122,500
2011		-
2012		-
2013		-
2014		-
Thereafter		-
Total	$	1,122,500
Less debt discount		-
	$	1,122,500

VYCOR MEDICAL, INC.

NOTES TO FINANCIAL STATEMENTS

JUNE 30, 2009 

15

4. LONG-TERM DEBT (CON’T)

The Company's entire long-term debt is secured by a first security interest in all of the assets of the Company.

5. EQUITY

Certain Equity Transactions

As prescribed in a previous agreement, in consideration for services provided to the Board of Directors, the Company issued 26,318 shares of its common stock to Steven Girgenti on March 23, 2009.

6. SHARE-BASED COMPENSATION

The Company accounts for the following transactions under the guidance of Emerging Issues Task Force Abstract No. 96-18, Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling Goods or Services. Under EIFT 96-18, options are recorded at their fair value on the measurement date. The Company remeasured the fair value of the options or warrants granted at each reporting period until performance under the consulting agreement was completed and the measurement date was reached. The Company expensed the fair value of the instrument granted over the requisite service period which was the term of the consulting agreement, or one year.

For employee based awards which consist only of awards made under the “Stock Option Plan” described below, the company follows the provisions of Statement of Financial Accounting Standards No. 123R (SFAS 123 R),  Share –Based Payment which requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. Under SFAS 123 R, compensation cost for employee cost for employee stock-based awards is based on the estimated grant-date fair value and recognized over the vesting period of the applicable award on a straight-line basis.  There were no employee stock options granted for the six months ended June 30, 2009.

Stock Option Plan

The Company has adopted the Vycor Medical, Inc Employee, Director, and Consultant Stock Plan as of February 13, 2008, that includes both incentive stock options and nonqualified stock options to be granted to employees, officers, and consultants, independent contractors, directors and affiliates of the Company.   The board of directors establishes the terms and conditions of all stock options grants, subject to the Plan and applicable provisions of the Internal Revenue Code.  Incentive stock options must be granted at an exercise price not less than the fair market value of the common stock on the grant date.  The options granted to participants owning more than 10% of the Company’s outstanding voting stock must be granted at an exercise price not less than 110% of the fair market value of the common stock on the grant date.  The options expire on the date determined by the board of directors, but may not extend mare than 10 years from the grant date, while incentive stock options granted to participants owning more than 10% of the Company’s outstanding voting stock expire five years from the grant date. The vesting period for employees is generally over three years.  The vesting Period for nonemployees is determined based on the services being provided.

Initial grants totaling 500,000 shares each were issued on February 13, 2008 to Kenneth T. Coviello, Chief Executive Officer and Heather N. Jensen, President at an exercise price of $.135 per share.  The options vest 33 1/3 % on each of the first, second, and third anniversary of the grant and expire February 12, 2018. Accordingly, for the

VYCOR MEDICAL, INC.

NOTES TO FINANCIAL STATEMENTS

16

JUNE 30, 2009

6. SHARE-BASED COMPENSATION (CON’T)

three months ended March 31, 2009, the Company recognized share-based compensation amounts of $28,920 and $28,920, for each of the respective grants.

The maximum number of shares of stock which maybe delivered under the plan shall automatically increase by a number sufficient to cause the number of shares covered by the plan to equal 10% of the total number of shares of stock then outstanding on a fully diluted basis.

Stock appreciation rights may be granted either on a stand alone basis or in conjunction with all or part of any other stock options granted under the plan.  As of June 30, 2009 there were no awards of any stock appreciation rights.

Consulting Agreements

The Company entered into no new consulting agreements during the six months ended June 30, 2009.

The details of the outstanding rights, options and warrants and value of such rights, options and warrants are as follows: 

STOCK WARRANTS:

	Number of shares		Weighted average exercise price per share
Balance, January 1, 2006
Granted		4,144,300	$	0.43
Exercised
Cancelled or expired
Outstanding at December 31, 2006		4,144,300		0.43
Granted		1,143,408		0.32
VYCOR MEDICAL, INC. NOTES TO FINANCIAL STATEMENTS

17

JUNE 30, 2009 6.SHARE-BASED COMPENSATION (CON’T) Exercised Cancelled or expired
Outstanding at December 31, 2007		5,287,708			0.41
Granted		1,365,788			0.31
Exercised
Cancelled or expired		(192,576	)		0.24
Outstanding at December 31, 2008		6,460,920		$	0.39
Granted
Exercised
Cancelled or expired		(850,468	)		0.26
Outstanding at June 30, 2009		5,610,452		$	0.39
STOCK OPTIONS:
				Weighted average
	Number of shares			exercise price per share
Balance, January 1, 2006
Granted		-		$	-
Exercised
Cancelled or expired
Outstanding at December 31, 2006		-			-

18

VYCOR MEDICAL, INC. NOTES TO FINANCIAL STATEMENTS JUNE 30, 2009 6.SHARE-BASED COMPENSATION (CON’T) Granted
Exercised
Cancelled or expired
Outstanding at December 31, 2007	-		-
Granted	1,050,000		0.14
Exercised
Cancelled or expired
Outstanding at December 31, 2008	1,050,000	$	0.14
Granted
Exercised
Cancelled or expired
Outstanding at June 30, 2009	1,050,000	$	0.14

In consideration for providing consulting services, the Company granted to GC Advisors LLC three warrants, each to purchase of 192,576 shares of the Company's common stock for a purchase price of $.24, .389, and .549 per share, respectively.  The warrants expire on January 9, 2008, 2009, and 2010, respectively and were fair valued under the Black-Scholes Model.

In consideration for being the Company's strategic business advisor, in 2007 the Company issued  a warrant to Martin Magida  to purchase up to 160,480 shares of the Company's common stock at $.24 per share. The warrant is valid from September 1, 2007 for a period of five years. This warrant was fair valued under the Black-Scholes Model and amortized over the life of the agreement. For the six months ended June 30, 2009, $2,228 was recognized as share-based compensation in connection with this agreement.

19

VYCOR MEDICAL, INC.

NOTES TO FINANCIAL STATEMENTS

JUNE 30, 2009

6. SHARE-BASED COMPENSATION (CON’T)

In consideration for providing advisory services in 2007, the Company issued a warrant to Robert Guinta to purchase up to 160,480 shares of the Company's common stock at $.24 per share. The warrant is valid from September 1, 2007 for a period of five years. This warrant was fair valued under the Black-Scholes Model and amortized over the life of the agreement. For the six months ended June 30, 2009, $2,228 was recognized as share-based compensation in connection with this agreement.

As of June 30, 2009, there was approximately $146,000 of total unrecognized compensation costs related to non-vested stock options awards, which are expected to be recognized over a weighted average period of 2 years.

Stock-based compensation expenses related to stock options granted to non-employees is recognized as the stock options are earned. The Company believes that the fair value of the stock options is more reliably measured than the fair value of the services received.  The fair value of the stock options granted is calculated at each reporting date, using the Black-Scholes option-pricing model, until the award vests or there is substantial disincentive for the non-employee not to perform the required services.  The following assumptions were used in calculations of the Black Scholes option pricing model:

Risk-free interest rates	4 - 5 %
Expected life	3 years
Expected dividends	0%
Expected volatility	99%

Stock-based compensation expense charged to operations on options and warrants granted to the above non-employees for the six months ended June 30, 2009 is $4,458.

Expected Life.  The expected life is based on the “simplified” method described in the SEC Staff Accounting Bulletin, Topic 14: Share-Based Payment.

Volatility.  Since the Company was a private entity for most of 2007 with no historical data regarding the volatility of its common stock, the expected volatility used for 2006 and 2007 is based on volatility of similar entities, referred to as “guideline” companies.  In evaluation similarity, the Company considered factors such as industry, stage of life cycle and size.

Risk-Free Interest Rate. The risk-free rate is based on rates approximating U.S. Treasury zero-coupon issues with remaining terms similar to the expected term on the options.

Dividend Yield.  The Company has never declared or paid any cash dividends and does not plan to pay cash dividends in the foreseeable future, and therefore, used an expected dividend yield of zero in the valuation method.

20

VYCOR MEDICAL, INC.

NOTES TO FINANCIAL STATEMENTS

JUNE 30, 2009

6. SHARE-BASED COMPENSATION (CON’T)

Forfeitures. SFAS No. 123R also requires the Company to estimate forfeitures at the time of grant, and revise those estimates in subsequent periods if actual forfeitures differ from those estimates.  The Company uses historical data, however limited to date, to estimate pre-vesting options forfeitures and record stock-based compensation expense only for those awards that are expected to vest.  All stock-based payment awards are amortized on a straight-line basis over the requisite service periods of awards, which are generally the vesting periods.  If the Company’s actual forfeiture rate is materially different from its estimate, the stock-based compensation expense could be significantly different from what the Company has recorded in the current period. 

The weighted-average remaining contractual life of outstanding warrants and options is two and two years, respectively.  All of the warrants outstanding are currently exercisable.

7. INCOME TAXES

The Company has incurred net operating losses since inception. The Company has not reflected any benefit of such net operating loss carry forward in the financial statements.  Prior to August 15, 2007 the Company was a limited liability company and losses were flowed through to the individual members, therefore the Company only has potential tax benefits from the date it became a ‘C’ corporation.

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income.

Based on the level of historical taxable losses and projections of future taxable income (losses) over the periods in which the deferred tax assets can be realized, management currently believes that it is more likely than not that the Company will not realize the benefits of these deductible differences. Accordingly, the Company has provided a valuation allowance against the gross deferred tax assets as follows:

June 30, 2009    December 31, 2008

Gross deferred tax assets	1,139,250		904,750
Valuation allowance	(1,139,250	)	(904,750	)
Net deferred tax asset	—		—

As of June 30, 2009 and December 31, 2008, the Company has estimated U.S. federal net operating loss carryforwards of approximately $3,255,000 and $2,585,000, respectively.  The federal net operating loss carryforwards expire in the years 2027 through 2029.

Federal tax laws impose significant restrictions on the utilization of net operating loss carryforwards and research and development credits in the event of a change in ownership of the Company, as defined by the Internal Revenue Code Section 382. The Company’s net operating loss carryforwards and research and development credits may be subject to the above limitations.

21

VYCOR MEDICAL, INC.

NOTES TO FINANCIAL STATEMENTS

JUNE 30, 2009

7. INCOME TAXES (CON’T)

The Company adopted the provisions of FASB Interpretation No. 48 (FIN 48), Accounting for Uncertainty in Income Taxes, on January 1, 2007.  Implementation of FIN 48 resulted in no adjustments to the Company’s liability for unrecognized tax benefits. As of both the date of adoption and as of December 31, 2008 there were no unrecognizable tax benefits. Accordingly, a tabular reconciliation from beginning to ending periods is not provided. The Company will classify any future interest and penalties as a component of income tax expense if incurred. To date, there have been no interest or penalties charged or accrued in relation to unrecognized tax benefits.

The Company is subject to federal and state examinations for the year 2006 forward. There are no tax examinations currently in progress.

8. COMMITMENTS AND CONTINGENCIES

Employment and Consulting Agreements

There were no new employment or consulting agreements executed during the six months ended June 30, 2009.

Lease

The Company leases its office space on a month to month basis. Rental expense for the six months ended June 30, 2009 and 2008 were $11,708 and $10,191, respectively.

SUBSEQUENT EVENTS

On July 30, 2009 the Company issued Senior Subordinated Debentures totaling $53,000 to Fountainhead Capital Management Limited and Regent Private Capital, LLC for proceeds of equivalent value. These debentures, due on or before August 31, 2009, accrue interest at the “Applicable Federal Rate” as defined by Internal Revenue Code. These are senior obligations of the Company, subordinate only to other existing debt instruments to these parties.

On July 31, 2009, the Company became in default on Senior Subordinated Debentures totaling $40,000 held by Fountainhead Capital Management Limited and Regent Private Capital, LLC. The Company is engaged in periodic discussions with the holders of these securities, however, as of this date there has been no definitive resolution of any of these defaults.

In accordance with existing consulting agreements, the Company issued the following common shares on July 28, 2009:

Steven Girgenti	26,316
Dr. Konstantin Slavin	39,145

On August 13, 2009, the Company received correspondence from one of its primary suppliers which ostensibly asserts that the Company owes the vendor approximately $117,000 on account of goods manufactured but not yet shipped and for certain allowances representing their claim of increases in the cost of producing goods. The Company has recorded the cost of all inventory it has previously received from this vendor, however, this additional amount has not been recorded as the goods have not shipped, been reviewed or accepted by the Company and is in dispute. The vendor has advised the Company that no further goods will be shipped to the Company until this matter is resolved to the satisfaction of the vendor.

22

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

Forward Looking Statements

This Form 10-Q contains some forward-looking statements. Forward-looking statements give our current expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. Forward-looking statements involve risks and uncertainties. Forward-looking statements include statements regarding, among other things, (a) our projected sales, profitability, and cash flows, (b) our growth strategies, (c) anticipated trends in our industries, (d) our future financing plans and (e) our anticipated needs for working capital. They are generally identifiable by use of the words “may,” “will,” “should,” “anticipate,” “estimate,” “plans,” “potential,” “projects,” “continuing,” “ongoing,” “expects,” “management believes,” “we believe,” “we intend” or the negative of these words or other variations on these words or comparable terminology. These statements may be found under “Management's Discussion and Analysis of Financial Condition and Results of Operations” and “Description of Business,” as well as in this Form 10-Q generally. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results.

Any or all of our forward-looking statements in this report may turn out to be inaccurate. They can be affected by inaccurate assumptions we might make or by known or unknown risks or uncertainties. Consequently, no forward-looking statement can be guaranteed. Actual future results may vary materially as a result of various factors, including, without limitation, the risks outlined under “Risk Factors” and matters described in this Form 10-Q generally. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements contained in this filing will in fact occur. You should not place undue reliance on these forward-looking statements.

The forward-looking statements speak only as of the date on which they are made, and, except to the extent required by federal securities laws, we undertake no obligation to publicly update any forward-looking statements, whether as the result of new information, future events, or otherwise.

Organizational History

We were formed as a limited liability company under the laws of the State of New York on June 17, 2005 as “Vycor Medical LLC”. On August 14, 2007, we converted into a Delaware corporation and changed our name to “Vycor Medical, Inc.” (“Delaware Corporation”). Our sole reason for conversion to the Delaware Corporation was to facilitate the raising of additional capital, as prospective investors had expressed resistance to investing in the Company as the NY LLC. At August 14, 2007, we had approximately 1,122 membership units of the NY LLC issued and outstanding. The managing members of the NY LLC determined, in their reasonable business judgment, that such units, in the aggregate, should convert to an aggregate of 17,999,999 shares of common stock of the Delaware Corporation. On this basis, we adopted a conversion ratio of 16,048 shares of common stock of the Delaware Corporation for each former unit of the NY LLC. Likewise, all conversion rights, options, warrants and any other rights to acquire units of the NY LLC (including but not limited to units issuable pursuant to the terms of the Fountainhead Bridge Loan Debenture, Fountainhead Warrant to purchase 50.22 units of the NY LLC, the Company’s Option Agreement with Fountainhead dated December 14, 2006), were converted to conversion rights, options, warrants and rights to acquire common shares of the Delaware Corporation, based on the same conversion ratio. The action authorizing the conversion was adopted by the unanimous consent of the Managing Members of the NY LLC pursuant to the terms of the NY LLC Operating Agreement.

Overview of Business

We are a developer of neurosurgical medical devices.  We have been conducting research, developing, prototyping, and producing mold development work for the Brain Access System. This product is designed to assist the neurosurgeon with brain surgery. It allows the surgeon to gain access to various regions in the brain through a working channel.

23

We are in the process of marketing our first series of products to the marketplace.  Our first product line that we introduced to the market is a new type of self retaining brain retractor called the ViewSite Brain Access System.  We started marketing the Brain Access System in September 2008 and started shipping all sizes in November 2008.  The product line consists of various port sizes and lengths to allow the surgeon to use the device for various regions of the brain and different procedures.

The second product in our pipeline is the Cervical Access System, which, pending receipt of additional funding and successful market testing, is planned for launch during 2010 pending funding. Like the Brain Access System, this product is designed to assist the surgeon in cervical surgeries, allowing the surgeon to gain access to the anterior cervical surgery site.

We have received FDA 510(k) clearance for both our Brain Access System and Cervical Access System products. Section 510(k) of the United States Food, Drug and Cosmetic Act requires medical device manufacturers to register with the U.S. Food and Drug Administration of their intent to market a medical device at least 90 days in advance. The 510(k) submission allows the U.S. Food and Drug Administration to determine whether a device is generally equivalent to any similar product already on the market. With the FDA 510(k) clearance, we are authorized to take our products to market in the U.S. without further approvals.

We have also received CE Marking for our products in September 2006 and are able to sell them in member countries of the European Union. The European Medical Device Directive makes it mandatory to fulfill CE certification requirements in order to export medical devices of Class I, IIa, IIb, and III to any country within the European community.

We believe that our Brain Access System and Cervical Access System products will replace standard retraction devices to establish a new standard of care in neurosurgery, leading to a broad and rapid adoption of our products.

Our Products

Our initial product applications for the retractor technology will be in neurological surgeries involving brain and spinal access.

We believe our Brain Access System offers several advantages over the brain retractor systems, commonly known as ribbon or blade retractors that are metallic and non transparent. When designing the products, we felt that if we can incorporate certain features into our products, the surgeon reaction and acceptance would be favorable. We attempted to incorporate the following features:

• gently separate delicate tissue;

• improve surgical outcomes (reducing potential surgeon and hospital liability), for example, decreased insertion tissue trauma, less need for readjustment during surgery and minimum interface surface pressures;

• increase surgical site access;

• provide superior field of vision and lighting;

• minimal invasive surgery;

The Brain Access System and Cervical Access System were invented by Dr. John Mangiardi. Dr. Mangiardi assigned the rights to the Brain Access System and Cervical Access System to Sawmill Trust on September 17, 2005 pursuant to an assignment agreement on the same date. Sawmill Trust then, in turn, assigned the same rights to us on September 17, 2005 pursuant to another assignment agreement dated the same date.

Brain Access System Products

The Brain Access System series of disposable products are used by the neurosurgeon to access the surgical site. This is done by inserting the Brain Access System through the brain tissue and then removing the Brain Access System introducer, leaving the remaining hollow working channel in place to provide the surgeon with access to the precise location desired for surgery.

24

The Brain Access System is available in multiple sizes and is a single-use product. We have designed multiple sizes and intend to add additional sizes in the future. During our design process we listed what product benefits would be of value to the neurosurgeons when using a retractor system. We then designed our product with the following intent:

• To minimize brain disruption during surgery by utilizing a tapered forward edge;

• To minimize venous pressure in the brain;

• To reduce “target shift” to allow the surgeon to reach the site accurately;

• To minimize off site healthy tissue damage;

• To allow for accurate neuronavigational image guidance systems (“IGS”) performance;

• To integrate with the leading surgical IGS systems such as Medtronics® and BrainLab®;

• To allow for easier positioning during surgery;

• To reduce damage to healthy brain tissue leading to shorter post-op recovery and reduced hospital stay; and

• To allow direct surgical visualization of brain tissue via optically transparent construction;

The extent to which we are successful in achieving the above objectives will be judged by the acceptance of the devices in the market.

The Brain Access System products have the potential to significantly reduce brain tissue trauma resulting from the currently used retractors and standard access procedures. First, the unique design of the product minimizes the size of the brain entry access necessary for surgical procedures, and in turn the amount of brain tissue exposed. For instance, a typical brain procedure involving the removal of a 7cm cystic astrocyctoma would result in an access site (corticotomy) of approximately 20mm. However, the same procedure that was performed utilizing the Company’s Brain Access System product required a corticotomy of only 2mm.

Furthermore, retractors that are currently in use are metallic and non-transparent. This requires the surgical team to maintain the retracted surface, typically by packing gauze around the access edges increasing movement and pressures over a greater portion of the brain and extending overall elapsed surgery times. We believe that the Brain Access System product eliminates this process, while providing better visibility for the surgeon and lower pressures on the retracted brain tissue.

Product shortcomings

Our products have a few shortcomings:

• One of the shortcomings of our products as compared to existing blade retractors is that our device diameter is fixed as opposed to variable. This gives the surgeon less flexibility once he is at the location unless he knows where he needs to go in the brain first.

• Another shortcoming is that the diameters and lengths of our devices are set to specific measurements, which limits the surgeon to these specific sizes.

• Depending on the case, usage of a disposable product may be viewed as costing more over time and may not be accepted by our potential customers.

IGS Opportunity for theBrain Access System

The VBAS product has the potential to significantly improve surgical acceptance and use of IGS (Image Guidance Systems) used in many surgeries, by addressing the two substantial IGS-related problems of target shifting and the lack of real-time retractor positioning data during procedures:

• Target Shifting

The normal surgical procedure utilizing standard retractors in brain surgery require pulling away the healthy tissue to expose the targeted region of the brain located underneath. However, in many cases, the amount of pulling required causes the targeted area to shift away from what is shown on the IGS system. This target shifting then requires the surgeon to cause additional trauma to healthy tissue and spend additional time as the shifted target

25

area is located and the retractor is repositioned. The VBAS system is designed to minimize or eliminate target shift, as the elliptical shape of the product distributes relatively uniform pressure on the surrounding brain tissue.

• Real-Time Retractor Positioning Data

Current retractor technology (commonly known as ribbon or blade retractors) is not well integrated with IGS systems. During insertion, the surgeon typically does not have real-time data to allow visualization of retractor insertion on the IGS monitor. The VBAS product line has been designed to adapt entirely to IGS systems, such that the use of a Brain Access System unit will allow the surgeon to see on the surgical monitor, in real-time, exactly where the retractor is in relation to critical brain structures and underlying pathologies. With the IGS enabled unit, the tip of the introducer is literally the “pointer” on the IGS system. The integration with the IGS systems must still be developed.

We plan on offering a version of all Brain Access System models that are IGS-friendly.

Brain Access System Product Models

The Brain Access System products consists of two models initially, namely, TC-VBAS and EC-VBAS and any additional models in the future, each designed to allow the surgeon the choice for specific brain surgeries for various procedures. Each of these models will be manufactured in various lengths to accommodate different depths for surgical access.

• TC-VBAS

The series consist of twelve disposable products, offered in four different port diameters of 12mm, 17mm, 21mm, and 28mm and a choice of three lengths for each of 3, 5, and 7cm.

• EC-VBAS

At present, this is available only in one size – 34mm x 5cm.

Cervical Access Products

The Cervical Access System products are to be used by the neurological surgeon to access the anterior cervical surgical site (the uppermost vertebrae located in the neck). This type of surgery is near very critical and delicate structures such as the larynx, esophagus and carotid artery. The shape of the Cervical Access System with the introducer lets the surgeon carefully place the device and the unique anchor screws then safely hold the access channel in place during the procedure. The clear body of the retractor allows the surgeon to see the entire field both during the insertion process as well as throughout the surgical procedure.

We have designed the Cervical Access System to:

• reduce the possibility of surrounding anatomic tissue damage, which include the trachea, esophagus, carotid artery, recurrent laryngeal and sympathetic nerve;

• minimize skin disruption with the utilization of tapered outward edges;

• eliminate retractor induced electrocautery burn injuries because it is made with surgical grade plastic materials;

• enable stable fixation (directly to the spinal column) in order to avoid accidental displacement and surrounding “tissue creep”; and

• allow for direct visualization of underlying anatomic structures using optically clear plastic.

Because our products have not been brought to market yet, there is no guarantee that any of the abovementioned features would prove effective and even so, be welcomed by the consumer.

Cervical Access System Product Models

26

The plan for the Cervical Access System series will consist of disposable products. The widths are able to accommodate from one to three levels of the cervical spine, from 26mm to 54mm. We are also evaluating a telescoping design that would reduce the number of sizes necessary and a version that incorporates a distractor. Further research and development is needed for a market-ready product.

Brain Retractors

Future plans include developing additional Brain Access System retractors to allow for access to various regions of the brain. This allows us to target more diverse neurosurgical specialties. We anticipate research and developing work starting in 2009 and estimate a research and development budget of $1,000,000 for 2009 and 2010, pending future funding.

Our plans are to eventually include retractor lines that are designed for the requirements of specific surgical applications like aneurisms, tumors and endoscopic work.

Intellectual Property

Patent Applications

Below is a table setting out the status and particulars of our patent applications:

FilingDate	ApplicationNo.	Country	Title	Status
June 22, 2005	60/692,959	US — provisional	Surgical Access Instruments for Use with Spinal or Orthopedic Surgery (Cervical)	Converted to PCT
June 22, 2006	PCT/US06/24243	PCT	Surgical Access Instruments for Use with Spinal or Orthopedic Surgery (Cervical)	National Phase Completed
June 22, 2005	11/155,175	US — utility	Surgical Access Instruments for Use with Delicate Tissues (Brain)	Final Office Action issued – response with one extension due August 23, 2009
November 27, 2006	PCT/US06/61246	PCT	Surgical Access Instruments for Use with Delicate Tissues (Brain)	National Phase Completed
June 22, 2006	2613323	Canada	Surgical Access Instruments for Use with Spinal or Orthopedic Surgery	Pending
June 22, 2006	06785312.7	Europe	Surgical Access Instruments for Use with Spinal or Orthopedic Surgery	Pending
June 22, 2006	299/KOLNP/2008	India	Surgical Access Instruments for Use with Spinal or Orthopedic Surgery	Pending
June 22, 2006	188321	Israel	Surgical Access Instruments for Use with Spinal or Orthopedic Surgery	Pending
June 22, 2006	2008-518369	Japan	Surgical Access Instruments for Use with Spinal or Orthopedic Surgery	Published
December 20, 2007	11/993,280	US – utility	Surgical Access Instruments	Notice of Missing

27

			for use with spinal or orthopedic surgery	Requirements – Decl/POA due September 9, 2009
June 25, 2008	08107050.4	Hong Kong	Surgical Access Instruments for use with spinal or orthopedic surgery	Pending
September 18, 2008	61/098041	US – provisional	Surgical Access Instruments for use with Delicate Tissues (Brain)	Convert to utility – foreign file due September 18, 2009
May 25, 2009		Canada	Surgical Access Instruments for use with Delicate Tissues (Brain)	Pending
May 26, 2009	06840022.5	Europe	Surgical Access Instruments for use with Delicate Tissues (Brain)	Voluntary Amendments due August 18, 2009
May 26, 2009	1977/KOLNP/2009	India	Surgical Access Instruments for use with Delicate Tissues (Brain)	Pending
May 27, 2009		Japan	Surgical Access Instruments for use with Delicate Tissues (Brain)	Examination due November 27, 2009
June 26, 2009	2009124446	Russia	Surgical Access Instruments for use with Delicate Tissues (Brain)	Examination due November 27, 2009
July 27, 2009		China	Surgical Access Instruments for use with Delicate Tissues (Brain)	Examination due November 27, 2009

The above-indicated patent applications were invented by Dr. John Mangiardi, who assigned the rights to the Sawmill Trust on September 17, 2005 under the terms of an assignment agreement between the parties. The Sawmill Trust then, in turn, assigned the same rights to us on September 17, 2005 pursuant to an assignment agreement between the Sawmill Trust and the Company dated the same date. The consideration for such assignment was the issuance of one-third of the initial equity of our predecessor (Vycor Medical, LLC) and the inclusion of certain rights in favor or the Sawmill Trust, including but not limited to certain supermajority voting rights and the right to appoint members of the board of managers, which were incorporated in the Operating Agreement of such entity. Dr. Mangiardi’s wife, Pascale Mangiardi, who is a director of the Company, was the Settlor of the Sawmill Trust and Dr and Mrs. Mangiardi are both beneficiaries of the Sawmill Trust. The Sawmill Trust is an irrevocable trust and A. Mitchell Green is the sole Trustee and has sole voting power and investment power with respect to the assets of the trust.

Trademarks

VYCOR MEDICAL is a registered trademark and VYCOR VIEWSITE is both pending registration as a trademark with the United States Patent Office

Results of Operations

Comparison of the Three Months Ended June 30, 2009 to the Three Months Ended June 30, 2008

The following table presents the dollar amount changes from period to period of the line-items included in our Statements of Operations for the three months ended June 30, 2009 and 2008:

Three months ended:	2009		2008		Increase/ (Decrease)
Revenue:
Sales	$	42,301	$	-	$	42,301

28

Cost of Goods Sold		5,331			-			5,331
Gross Profit		36,970			-			36,970
Operating expenses:
Research and development		-			9,228			(9,228	)
General and administrative		234,045			381,365			(147,320	)
Operating loss		(197,075	)		(390,593	)		193,518
Interest Expense		54,639			157,099			(102,460	)
Net loss	$	(251,714	)	$	(547,692	)	$	295,978

Revenue:

For the three months ended June 30, 2009, the company recorded revenue of $42,301, after posting no revenue from the sale of our products in the three months ended June 30, 2008. The company has acquired sufficient inventory, affected a meaningful product launch, and has sold various quantities of each of the twelve sizes of its Brain Access System product to both domestic and international customers.

Research and Development Expenses:

Research and development expenses decreased from $9,228 to $0 for the three months ended June 30, 2009.  This decrease can be attributed to the ceasing of research and development activities on the existing product line.

General and Administrative Expenses:

General and administrative expenses decreased by 38.63%, or $147,320 from $381,365 for the three months ended June 30, 2008 to $234,045 for the three months ended June 30, 2009. The decrease was attributable to the elimination of certain nonrecurring legal and consulting costs related to the company’s capital transactions in 2008.

Interest Expense (Income):

The company recorded interest expense of $54,639 and $157,099 for the three months ended June 30, 2009 and 2008, respectively. The decrease occurred since the majority of the debt discount attributable to the company’s existing convertible debt was recognized prior to the three months ended June 30, 2009.  For the three months ended June 30, 2009 and 2008, interest expense was offset with interest income of $45 and $2,527, respectively.

Comparison of the Six Months Ended June 30, 2009 to the Six Months Ended June 30, 2008

The following table presents the dollar amount changes from period to period of the line-items included in our Statements of Operations for the six months ended June 30, 2009 and 2008:

Six months ended:	2009			2008			Increase/ (Decrease)
Revenue:
Sales	$	112,389		$	-		$	112,389
Cost of Goods Sold		14,834			-			14,834
Gross Profit		97,555			-			97,555
Operating expenses:
Research and development		-			15,561			(15,561	)
General and administrative		576,011			859,993			(283,982	)
Operating loss		(478,456	)		(875,554	)		397,098
Interest Expense		193,393			250,598			(57,205	)
Net loss	$	(671,849	)	$	(1,126,152	)	$	454,303

Revenue:

29

For the six months ended June 30, 2009, the company recorded revenue of $112,389, after posting no revenue from the sale of our products in the six months ended June 30, 2008. The company has acquired sufficient inventory, affected a meaningful product launch, and has sold various quantities of each of the twelve sizes of its Brain Access System product to both domestic and international customers.

Research and Development Expenses:

Research and development expenses decreased from $15,561 to $0 for the six months ended June 30, 2009.  This decrease can be attributed to the ceasing of research and development activities on the existing product line.

General and Administrative Expenses:

General and administrative expenses decreased by 33.02%, or $283,982 from $859,993 for the six months ended June 30, 2008 to $576,011 for the six months ended June 30, 2009. The decrease was attributable to the elimination of certain nonrecurring legal and consulting costs related to the company’s capital transactions in 2008.

Interest Expense (Income):

The company recorded interest expense of $193,393 and $250,598 for the six months ended June 30, 2009 and 2008, respectively. The decrease occurred since the majority of the debt discount attributable to the company’s existing convertible debt was recognized prior to the six months ended June 30, 2009. For the six months ended June 30, 2009 and 2008, interest expense was offset with interest income of $246 and $4,231, respectively.

Liquidity and Capital Resources

Liquidity

On February 15, 2008, the company entered into a transaction with Regent Private Capital, LLC, whereby Regent Private Capital, LLC agreed to invest $1,000,000 in the purchase of the company’s Convertible Debentures—such investment to be made in two tranches of $500,000 each.  These Convertible Debentures have a term of one year and are convertible into shares of the our common stock at a price of approximately $.123 per share. If fully converted, the Convertible Debentures would result in the issuance of 8,129,529 shares to Regent Private Capital, LLC.  On April 22, 2008 Regent Private Capital assigned $250,000 of the principal amount of the Convertible Debentures representing the first tranche to Derek Johannson and $100,000 of the principal amount of the Convertible Debentures to Altcar Investments Ltd.  On December 2, 2008 Derek Johannson converted $250,000 of his debenture to 2,032,520 shares of common stock of the company. On March 23, 2009, Altcar Investments converted $100,000 of the debenture plus accrued interest of $6,625 into 866,867 shares of common stock.

For the six months ended June 30, 2009, the Company issued common stock valued at $5,000 for consulting services.  During the same period, share-based compensation of $62,297 was recognized relating to previously executed consulting agreements and the vesting of employee-held options.

For the six months ended June 30, 2009, the Company realized a reduction in cash and cash equivalents of $141,211.  This amount was entirely attributable to cash used in operating activities, as there was no cash used in or provided by either investing or financing transactions during the period.

The company believes that its existing cash, cash equivalents and available borrowings will only be sufficient to meet our anticipated cash needs for working capital and capital expenditures for a very limited period. The company will need to immediately seek additional funding through public or private financings or other arrangements on a current basis and hereafter. Adequate funds may not be available when needed or may not be available on terms favorable to us. If additional funds are raised by issuing equity securities, dilution to existing stockholders may result. If the company raises additional funds by obtaining loans from third parties, the terms of those financing arrangements may include negative covenants or other restrictions on our business that could impair our operational flexibility, and would also require us to fund additional interest expense. If funding is insufficient at any time in the future, the company may be unable to develop or enhance our products, take advantage of business opportunities or respond to competitive pressures, any of which could have a material adverse effect on our business, financial condition and results of operations.

30

Going Concern

Our independent auditors have added an explanatory paragraph to their audit issued in connection with the financial statements for the period ended December 31, 2008, relative to our ability to continue as a going concern. This means that there is substantial doubt that the company can continue as an ongoing business for the next 12 months. The financial statements do not include any adjustments that might result from the uncertainty about our ability to continue our business. The company has incurred losses since inception, including net losses of $2,381,295 for the year ended December 31, 2008 and $671,849 for the six months ended June 30, 2009, and expects to incur substantial additional losses, including additional development costs, costs related to marketing and manufacturing expenses. The company has incurred negative cash flows from operations since inception. As of June 30, 2009 and December 31, 2008, the company had stockholders’ deficiencies of $1,419,355 and $921,427, respectively, and cash and cash equivalents balance of $54,927 and $196,138 at June 30, 2009 and December 31, 2008, respectively. The Company also has certain debt obligations that were not paid by their respective due dates. Since there is no record of profitable operations, there is high a possibility that you may suffer a complete loss of your investment.  Because our auditors have issued a going concern opinion, there is substantial uncertainty we will continue operations in which case you could lose your investment.  In these circumstances the Company believes it may not have enough cash to meet its various cash needs through August 2009 unless the Company is able to obtain additional cash from the issuance of debt or equity securities.  There is no assurance that additional funds from the issuance of equity will be available for the Company to finance its operations on acceptable terms. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.

Recently Issued Accounting Pronouncements

The Company has adopted all recently issued accounting pronouncements. The adoption of the accounting pronouncements, including those not yet effective, is not anticipated to have a material effect on the financial position or results of operations of the Company.

Critical Accounting Policies and Estimates

Uses of estimates in the preparation of financial statements

The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Currently, the Company estimates depreciation, amortization of intangible assets, and the fair values of options and warrants.

The most critical estimates that impact the financial position and results of operation of the company have to do with the methodologies and assumptions used in determining the fair value of various debt estimates. These include assumptions associated with warrants, options and stock issued in conjunction with such debt. Additionally, the Black-Scholes option pricing model and its related assumptions of volatility, risk free interest, stock price also significantly impacted share based compensation and the results of operations.

Research and Development

The Company expenses all research and development costs as incurred. For the six months ended June 30, 2009 and 2008, the amounts charged to research and development expenses were $ 0 and $15,561, respectively.

Cash and cash equivalents

The Company considers all highly liquid debt investments with original maturities of six months or less when purchased to be cash equivalents. The carrying amounts approximate fair market value because of the short maturity. The Company maintains cash balances at various financial institutions. Accounts at each institution are insured by the Federal Deposit Insurance Corporation up to $250,000. The Company's accounts at these institutions may, at times, exceed the federally insured limits. The Company has not experienced any losses in such accounts.

31

Fair Values of Financial Instruments

At June 30, 2009 and 2008, fair values of cash and cash equivalents, accounts payable, convertible promissory notes, and options and warrants approximate their carrying amount due to the short period of time to maturity and various fair value model calculations.

Property and equipment

The Company records property and equipment at cost and calculates depreciation using the straight-line method over the estimated useful life of the assets, which is estimated to be between three and ten years.

Income taxes

The Company accounts for income taxes in accordance with SFAS 109, Accounting for Income Taxes.  This statement prescribes the use of the liability method whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value.

Patents

The Company capitalizes legal and related costs associated with the establishment of patents for its products. Costs associated with the development of the patented item or process are charged to research and development costs as incurred. The costs associated with the establishment of the patents are amortized over the life of the patent.

The Company reviews existing patents as well as those in the approval process for impairment on an annual basis using a present value, cash flow method pursuant to Statement of Financial Accounting Standards 142, Goodwill and Other Intangible Assets. Since the Company’s patents are either very new or still in the process of approval, the Company does not believe that any impairment of these amounts exists.

Revenue Recognition

The Company records revenue at the time, pursuant to Staff Accounting Bulletin Topic 13(a), that a completed contract for the sale exists, title transfers to the buyer and the product is invoiced and shipped to the customer. The Company intends to sell a surgical access system which has already cleared the U.S. FDA 510(k) review process.  It has been granted a 510(k) number to market to hospitals and other medical professionals.  The Company does not expect the need to provide for product returns or warrantee costs but will review such potential costs after the commencement of sales.

Educational and marketing expenses

The Company may incur costs for the education of customers on the uses and benefits of its products. The Company will expense such costs as a component of selling, general and administrative costs as such costs are incurred.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable

ITEM 4. CONTROLS AND PROCEDURES

(a)   Disclosure Controls and Procedures

The Company’s management, with the participation of its principal executive officer and principal financial officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, the Company’s principal

32

executive officer and principal financial officer have concluded that, as of the end of such period, the Company’s disclosure controls and procedures were adequate and effective.

(b)   Changes in Internal Controls

There have not been any changes in the Company’s internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended June 30, 2009 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II

ITEM 1. LEGAL PROCEEDINGS

We are subject from time to time to litigation, claims and suits arising in the ordinary course of business. As of June 30, 2009, we were not a party to any material litigation, claim or suit whose outcome could have a material effect on our financial statements.

ITEM 2 UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None

ITEM 3 DEFAULTS UPON SENIOR SECURITIES

The Company is in default on the following Senior Securities:

a) Convertible Debenture in the original face amount of $150,000 in favor of Fountainhead Capital Partners Limited dated February 15, 2008 which matured on February 15, 2009;

b) Convertible Debenture in the original face amount of $150,000 in favor of Regent Private Capital, LLC dated February 15, 2008 which matured on February 15, 2009;

c) Convertible Debenture in the original face amount of $150,000 in favor of Fountainhead Capital Partners Limited dated April 15, 2008 which matured on April 15, 2009;

d) Convertible Debenture in the original face amount of $500,000 in favor of Regent Private Capital, LLC dated April 22, 2008 which matured on April 22, 2009;

e) Senior Subordinated Debenture in the original face amount of $40,000 in favor of Fountainhead Capital Partners Limited and Regent Private Capital, LLC dated June 30, 2009 which matured on July 31, 2009.

The Company is engaged in periodic discussions with the holders of these securities, however, as of this date there has been no definitive resolution of any of these defaults.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None.

ITEM 5. OTHER INFORMATION

SUBSEQUENT EVENTS

On July 30, 2009 the Company issued Senior Subordinated Debentures totaling $53,000 to Fountainhead Capital Management Limited and Regent Private Capital, LLC for proceeds of equivalent value. These debentures, due on or before August 31, 2009, accrue interest at the “Applicable Federal Rate” as defined by Internal Revenue Code. These are senior obligations of the Company, subordinate only to other existing debt instruments to these parties.

33

On July 31, 2009, the Company became in default on Senior Subordinated Debentures totaling $40,000 held by Fountainhead Capital Management Limited and Regent Private Capital, LLC. There is no existing plan to cure said default at this time.

In accordance with existing consulting agreements, the Company issued the following common shares on July 28, 2009:

Steven Girgenti	26,316
Dr. Konstantin Slavin	39,145

On August 13, 2009, the Company received correspondence from one of its primary suppliers which ostensibly asserts that the Company owes the vendor approximately $117,000 on account of goods manufactured but not yet shipped and for certain allowances representing their claim of increases in the cost of producing goods. The Company has recorded the cost of all inventory it has previously received from this vendor, however, this additional amount has not been recorded as the goods have not shipped, been reviewed or accepted by the Company and is in dispute. The vendor has advised the Company that no further goods will be shipped to the Company until this matter is resolved to the satisfaction of the vendor.

ITEM 6. EXHIBITS

Index to Exhibits

31.1	Certification of Chief Executive Officer under Rule 13(a) - 14(a) of the Exchange Act.
31.2	Certification of Chief Financial Officer under Rule 13(a) - 14(a) of the Exchange Act.
32	Certification of CEO and CFO under 18 U.S.C. Section 1350

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on August 14, 2009.

VYCOR MEDICAL, INC.
By:	/s/ Kenneth T. Coviello
	Kenneth T. Coviello
	Chief Executive Officer and Director (Principal Financial Officer)
By:	/s/ Heather N. Jensen
	Heather N. Jensen
	President, Founder and Director (Principal Executive Officer)

34